Loading...

Cummings Jeffrey

TitleProfessor
InstitutionUniversity of California Los Angeles
DepartmentNeurology
Address10911 Weyburn Ave. Suite 200
Los Angeles CA 90095
Phone(310)794-3665
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease
    NIH/NIA R01AG053798May 1, 2017 - Apr 30, 2022
    Role: Co-Principal Investigator
    Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors
    NIH/NINDS U01NS093334Dec 15, 2015 - Nov 30, 2022
    Role: Co-Principal Investigator
    COBRE GRANT
    NIH/NIGMS P20GM109025Sep 1, 2015 - May 31, 2020
    Role: Principal Investigator
    Dementia and Disability in Thai Elderly
    NIH/FIC R03TW006426Jul 15, 2003 - Jun 30, 2007
    Role: Principal Investigator
    UCLA Alzheimer's Disease Research Center
    NIH/NIA P50AG016570Apr 5, 1999 - Mar 31, 2015
    Role: Co-Principal Investigator
    LOS ANGELES AREA ALZHEIMER'S OUTREACH PROGRAM (LAAAOP)
    NIH/NIA R25AG011325Sep 30, 1992 - Jun 30, 1998
    Role: Principal Investigator
    UCLA ALZHEIMERS DISEASE CENTER
    NIH/NIA P30AG010123Sep 30, 1991 - Jun 30, 2001
    Role: Principal Investigator
    DEMENTIA AND BEHAVIORAL NEUROLOGY: RESEARCH FELLOWSHIP
    NIH/NIA T32AG000172Sep 1, 1988 - Apr 30, 2004
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Miller JB, Cummings J, Nance C, Ritter A. Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience. Alzheimers Dement (N Y). 2018; 4:350-356. PMID: 30175229.
      View in: PubMed
    2. Torosyan N, Sethanandha C, Grill JD, Dilley ML, Lee J, Cummings JL, Ossinalde C, Silverman DH. Changes in regional cerebral blood flow associated with a 45?day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study. Exp Gerontol. 2018 Jul 10. PMID: 30006299.
      View in: PubMed
    3. Cummings J. The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. Alzheimers Dement. 2018 Jun 21. PMID: 29936146.
      View in: PubMed
    4. Cordes D, Zhuang X, Kaleem M, Sreenivasan K, Yang Z, Mishra V, Banks SJ, Bluett B, Cummings JL. Advances in functional magnetic resonance imaging data analysis methods using Empirical Mode Decomposition to investigate temporal changes in early Parkinson's disease. Alzheimers Dement (N Y). 2018; 4:372-386. PMID: 30175232.
      View in: PubMed
    5. Shan G, Banks S, Miller JB, Ritter A, Bernick C, Lombardo J, Cummings JL. Statistical advances in clinical trials and clinical research. Alzheimers Dement (N Y). 2018; 4:366-371. PMID: 30175231.
      View in: PubMed
    6. Cummings J, Reiber C, Kumar P. The price of progress: Funding and financing Alzheimer's disease drug development. Alzheimers Dement (N Y). 2018; 4:330-343. PMID: 30175227.
      View in: PubMed
    7. Cummings JL, Fulkerson N. Neurodegeneration research: Advances in clinical translational neuroscience infrastructure and methods. Alzheimers Dement (N Y). 2018; 4:326-329. PMID: 30167452.
      View in: PubMed
    8. Caldwell JZK, Berg JL, Shan G, Cummings JL, Banks SJ. Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume. J Alzheimers Dis. 2018 May 26. PMID: 29865063.
      View in: PubMed
    9. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (N Y). 2018; 4:195-214. PMID: 29955663.
      View in: PubMed
    10. Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med. 2018 05 03; 378(18):1691-1703. PMID: 29719179.
      View in: PubMed
    11. Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, Leibensperger H, Snow-Adami L, McMahon KB, Egan M, Michelson D. Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease. Alzheimers Dement (N Y). 2018; 4:173-181. PMID: 29955661.
      View in: PubMed
    12. Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018 Apr 25. PMID: 29695589.
      View in: PubMed
    13. Cummings J, Ritter A, Zhong K. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. J Alzheimers Dis. 2018 Mar 16. PMID: 29562511.
      View in: PubMed
    14. Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, Youakim JM, Owen R, Stankovic S. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018 Mar; 17(3):213-222. PMID: 29452684.
      View in: PubMed
    15. Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, Cummings J, Dubois B, Federoff HJ, Fiandaca M, Genthon R, Haberkamp M, Karran E, Mapstone M, Perry G, Schneider LS, Welikovitch LA, Woodcock J, Baldacci F, Lista S. Precision pharmacology for Alzheimer's disease. Pharmacol Res. 2018 Apr; 130:331-365. PMID: 29458203.
      View in: PubMed
    16. Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. JAMA. 2018 01 09; 319(2):130-142. PMID: 29318278.
      View in: PubMed
    17. Berg JL, Durant J, Léger GC, Cummings JL, Nasreddine Z, Miller JB. Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study. J Alzheimers Dis. 2018; 62(1):93-97. PMID: 29439349.
      View in: PubMed
    18. Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology. 2018 Jan 09; 90(2):74-82. PMID: 29237794.
      View in: PubMed
    19. Cummings J. Disease modification and Neuroprotection in neurodegenerative disorders. Transl Neurodegener. 2017; 6:25. PMID: 29021896.
      View in: PubMed
    20. Caldwell JZK, Berg JL, Cummings JL, Banks SJ. Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume. Alzheimers Res Ther. 2017 Sep 12; 9(1):72. PMID: 28899422.
      View in: PubMed
    21. Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B. On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimers Res Ther. 2017 Aug 09; 9(1):60. PMID: 28793924.
      View in: PubMed
    22. Cummings J. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. Clin Transl Sci. 2018 Mar; 11(2):147-152. PMID: 28767185.
      View in: PubMed
    23. Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2017. Alzheimers Dement (N Y). 2017 Sep; 3(3):367-384. PMID: 29067343.
      View in: PubMed
    24. Cummings J, Scheltens P, McKeith I, Blesa R, Harrison JE, Bertolucci PH, Rockwood K, Wilkinson D, Wijker W, Bennett DA, Shah RC. Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease. J Alzheimers Dis. 2017; 55(3):1131-1139. PMID: 27767993.
      View in: PubMed
    25. Bloniecki V, Aarsland D, Blennow K, Cummings J, Falahati F, Winblad B, Freund-Levi Y. Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. J Alzheimers Dis. 2017; 57(2):387-393. PMID: 28269767.
      View in: PubMed
    26. Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J, Lanctôt KL, Miller DS, Mortby ME, Onyike CU, Rosenberg PB, Smith EE, Smith GS, Sultzer DL, Lyketsos C. The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. J Alzheimers Dis. 2017; 56(3):929-938. PMID: 28059789.
      View in: PubMed
    27. Rinne JO, Wesnes K, Cummings JL, Hakulinen P, Hallikainen M, Hänninen J, Murphy M, Riordan H, Scheinin M, Soininen H, Rouru J. Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. Alzheimers Dement (N Y). 2017 Jan; 3(1):1-9. PMID: 29067315.
      View in: PubMed
    28. Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther. 2016 Sep 20; 8:39. PMID: 27646601; PMCID: PMC5028936.
    29. Cummings J, Morstorf T, Lee G. Alzheimer's drug-development pipeline: 2016. Alzheimers Dement (N Y). 2016 Nov; 2(4):222-232. PMID: 29067309.
      View in: PubMed
    30. Kim HJ, Choi KH, Kim SH, Cummings JL, Yang DW. Validation Study of the Korean Version of the Brief Clinical Form of the Neuropsychiatric Inventory. Dement Geriatr Cogn Dis Extra. 2016 May-Aug; 6(2):214-21. PMID: 27350782; PMCID: PMC4913765.
    31. Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, Dhadda S, Do I, Rabe M, Luthman J, Cummings J, Satlin A. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. J Neurol Neurosurg Psychiatry. 2016 09; 87(9):993-9. PMID: 27010616.
      View in: PubMed
    32. Cummings JL, Siffert J. Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply. JAMA. 2016 Mar 15; 315(11):1166-7. PMID: 26978215.
      View in: PubMed
    33. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar; 12(3):292-323. PMID: 27012484.
      View in: PubMed
    34. Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, Pontecorvo M, Devous M, Tang A, Bena J. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease. Alzheimers Res Ther. 2016 Jan 29; 8:4. PMID: 26822146; PMCID: PMC4731943.
    35. Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, Dash A. Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies. CNS Neurosci Ther. 2016 Mar; 22(3):159-66. PMID: 26778658.
      View in: PubMed
    36. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer's disease. Nat Rev Dis Primers. 2015 10 15; 1:15056. PMID: 27188934.
      View in: PubMed
    37. Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, De La Gandara JE, Agronin M, Davis CS, Nguyen U, Shin P, Tariot PN, Siffert J. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA. 2015 Sep 22-29; 314(12):1242-54. PMID: 26393847.
      View in: PubMed
    38. Ritter A, Cummings J. Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. Front Neurol. 2015; 6:186. PMID: 26379620; PMCID: PMC4553391.
    39. Vogel SJ, Banks SJ, Cummings JL, Miller JB. Concordance of the Montreal cognitive assessment with standard neuropsychological measures. Alzheimers Dement (Amst). 2015 Sep; 1(3):289-94. PMID: 27239512; PMCID: PMC4877929.
    40. Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Res Ther. 2015; 7(1):39. PMID: 26120368; PMCID: PMC4481112.
    41. Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J. Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimers Res Ther. 2015; 7(1):43. PMID: 26120369; PMCID: PMC4481070.
    42. Yuan J, Zhang Z, Wen H, Hong X, Hong Z, Qu Q, Tang M, Wu J, Xu Q, Li H, Cummings JL. Incidence of dementia and subtypes: A cohort study in four regions in China. Alzheimers Dement. 2016 Mar; 12(3):262-71. PMID: 26086181.
      View in: PubMed
    43. Mao HF, Kuo CA, Huang WN, Cummings JL, Hwang TJ. Values of the Minimal Clinically Important Difference for the Neuropsychiatric Inventory Questionnaire in Individuals with Dementia. J Am Geriatr Soc. 2015 Jul; 63(7):1448-52. PMID: 26046666.
      View in: PubMed
    44. Kershaw S, Cummings J, Morris K, Tugwood J, Dive C. Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells. BMC Cancer. 2015 May 10; 15:387. PMID: 25957999; PMCID: PMC4436118.
    45. Cummings J, Friedman JH, Garibaldi G, Jones M, Macfadden W, Marsh L, Robert PH. Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials. J Geriatr Psychiatry Neurol. 2015 Sep; 28(3):159-73. PMID: 25809634.
      View in: PubMed
    46. Molinuevo JL, Frölich L, Grossberg GT, Galvin JE, Cummings JL, Krahnke T, Strohmaier C. Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch. Alzheimers Res Ther. 2015; 7(1):9. PMID: 25755685; PMCID: PMC4353453.
    47. Ringman JM, Liang LJ, Zhou Y, Vangala S, Teng E, Kremen S, Wharton D, Goate A, Marcus DS, Farlow M, Ghetti B, McDade E, Masters CL, Mayeux RP, Rossor M, Salloway S, Schofield PR, Cummings JL, Buckles V, Bateman R, Morris JC. Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. Brain. 2015 Apr; 138(Pt 4):1036-45. PMID: 25688083.
      View in: PubMed
    48. Cummings JL, Isaacson RS, Schmitt FA, Velting DM. A practical algorithm for managing Alzheimer's disease: what, when, and why? Ann Clin Transl Neurol. 2015 Mar; 2(3):307-23. PMID: 25815358; PMCID: PMC4369281.
    49. Petersen RB, Lissemore FM, Appleby B, Aggarwal N, Boyatzis R, Casadesus G, Cummings J, Jack A, Perry G, Safar J, Sajatovic M, Surewicz WK, Wang Y, Whitehouse P, Lerner A. From Neurodegeneration to Brain Health: An Integrated Approach. J Alzheimers Dis. 2015; 46(1):271-83. PMID: 25720413.
      View in: PubMed
    50. Raskin J, Cummings J, Hardy J, Schuh K, Dean RA. Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Curr Alzheimer Res. 2015; 12(8):712-22. PMID: 26412218.
      View in: PubMed
    51. Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. J Alzheimers Dis. 2015; 43(3):949-55. PMID: 25125457.
      View in: PubMed
    52. Arias JJ, Cummings J, Grant AR, Ford PJ. Stakeholders' Perspectives on Preclinical Testing for Alzheimer's Disease. J Clin Ethics. 2015; 26(4):297-305. PMID: 26752383.
      View in: PubMed
    53. Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. J Alzheimers Dis. 2015; 47(1):205-14. PMID: 26402769; PMCID: PMC4923754.
    54. Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, Cummings J. The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Dis Extra. 2014 Sep-Dec; 4(3):509-16. PMID: 25685141; PMCID: PMC4307008.
    55. Shen JH, Shen Q, Yu H, Lai JS, Beaumont JL, Zhang Z, Wang H, Kim SY, Chen C, Kwok T, Wang SJ, Lee DY, Harrison J, Cummings J. Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease. Am J Neurodegener Dis. 2014; 3(3):158-69. PMID: 25628967; PMCID: PMC4299719.
    56. Cummings J, Mintzer J, Brodaty H, Sano M, Banerjee S, Devanand DP, Gauthier S, Howard R, Lanctôt K, Lyketsos CG, Peskind E, Porsteinsson AP, Reich E, Sampaio C, Steffens D, Wortmann M, Zhong K. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. Int Psychogeriatr. 2015 Jan; 27(1):7-17. PMID: 25311499; PMCID: PMC4301197.
    57. Bloniecki V, Aarsland D, Cummings J, Blennow K, Freund-Levi Y. Agitation in dementia: relation to core cerebrospinal fluid biomarker levels. Dement Geriatr Cogn Dis Extra. 2014 May; 4(2):335-43. PMID: 25298777; PMCID: PMC4176467.
    58. Cummings JL, Tribanek M, Hoerr R. Sensitivity to change of composite and frequency scores of the neuropsychiatric inventory in mild cognitive impairment. Int Psychogeriatr. 2014 Nov; 26(11):1871-4. PMID: 24990088.
      View in: PubMed
    59. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014; 6(4):37. PMID: 25024750; PMCID: PMC4095696.
    60. Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, Fillit HM. Overcoming obstacles to repurposing for neurodegenerative disease. Ann Clin Transl Neurol. 2014 Jul; 1(7):512-8. PMID: 25356422; PMCID: PMC4184781.
    61. Miller JB, Banks SJ, Léger GC, Cummings JL. Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes. Transl Neurodegener. 2014; 3:12. PMID: 24921043; PMCID: PMC4052335.
    62. Pillai JA, Bonner-Jackson A, Walker E, Mourany L, Cummings JL. Higher working memory predicts slower functional decline in autopsy-confirmed Alzheimer's disease. Dement Geriatr Cogn Disord. 2014; 38(3-4):224-33. PMID: 24903099; PMCID: PMC4140977.
    63. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014 Jun; 13(6):614-29. PMID: 24849862.
      View in: PubMed
    64. Bradley P, Akehurst R, Ballard C, Banerjee S, Blennow K, Bremner J, Broich K, Cummings J, Dening K, Dubois B, Klipper W, Leibman C, Mantua V, Molinuevo JL, Morgan S, Muscolo LA, Nicolas F, Pani L, Robinson L, Siviero P, van Dam J, Van Emelen J, Wimo A, Wortmann M, Goh L. Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. Alzheimers Dement. 2015 Apr; 11(4):455-61. PMID: 24751826.
      View in: PubMed
    65. Cummings JL, Ringman J, Vinters HV. Neuropathologic correlates of trial-related instruments for Alzheimer's disease. Am J Neurodegener Dis. 2014; 3(1):45-9. PMID: 24754002; PMCID: PMC3986610.
    66. Cummings J, Sloane R, Morris K, Zhou C, Lancashire M, Moore D, Elliot T, Clarke N, Dive C. Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells. BMC Cancer. 2014 Mar 28; 14:226. PMID: 24674711; PMCID: PMC3977890.
    67. Cummings JL, Fine MJ, Grachev ID, Jarecke CR, Johnson MK, Kuo PH, Schaecher KL, Oberdorf JA, Rezak M, Riley DE, Truong D. Effective and efficient diagnosis of parkinsonism: the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan™). Am J Manag Care. 2014 Mar; 20(5 Suppl):S97-109. PMID: 24773455.
      View in: PubMed
    68. McLaughlin PM, Wright MJ, Larocca M, Nguyen PT, Teng E, Apostolova LG, Ringman JM, Zhou Y, Cummings JL, Woo E. The "Alzheimer's type" profile of semantic clustering in amnestic mild cognitive impairment. J Int Neuropsychol Soc. 2014 Apr; 20(4):402-12. PMID: 24521694; PMCID: PMC4086918.
    69. Cummings JL, Zhong K. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. Expert Rev Clin Pharmacol. 2014 Mar; 7(2):161-5. PMID: 24502586.
      View in: PubMed
    70. Apostolova LG, Di LJ, Duffy EL, Brook J, Elashoff D, Tseng CH, Fairbanks L, Cummings JL. Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease. Dement Geriatr Cogn Disord. 2014; 37(5-6):315-26. PMID: 24481207; PMCID: PMC4057985.
    71. Cummings J, Zhong K, Bernick C. The Cleveland Clinic Lou Ruvo Center for Brain Health: keeping memory alive. J Alzheimers Dis. 2014; 38(1):103-9. PMID: 23948939.
      View in: PubMed
    72. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 08; 383(9916):533-40. PMID: 24183563.
      View in: PubMed
    73. Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, Little R, Parker GJ, Potter P, Saunders M, Roberts C, Shaw D, Smith N, Smythe J, Taylor A, Turner H, Watson Y, Dive C, Jayson GC. A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1343-52. PMID: 24141375.
      View in: PubMed
    74. Cummings J, Morris K, Zhou C, Sloane R, Lancashire M, Morris D, Bramley S, Krebs M, Khoja L, Dive C. Method validation of circulating tumour cell enumeration at low cell counts. BMC Cancer. 2013 Sep 11; 13:415. PMID: 24024881; PMCID: PMC3848977.
    75. Grossberg G, Cummings J, Frölich L, Bellelli G, Molinuevo JL, Krahnke T, Strohmaier C. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2013 Sep; 28(6):583-91. PMID: 23982674.
      View in: PubMed
    76. Sabbagh JJ, Kinney JW, Cummings JL. Alzheimer's disease biomarkers in animal models: closing the translational gap. Am J Neurodegener Dis. 2013; 2(2):108-20. PMID: 23844335; PMCID: PMC3703123.
    77. Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, Mackell J, Fain R. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. BMC Geriatr. 2013 Jun 06; 13:56. PMID: 23742728; PMCID: PMC3681558.
    78. Sabbagh JJ, Kinney JW, Cummings JL. Alzheimer's disease biomarkers: correspondence between human studies and animal models. Neurobiol Dis. 2013 Aug; 56:116-30. PMID: 23631871.
      View in: PubMed
    79. Trzepacz PT, Saykin A, Yu P, Bhamditipati P, Sun J, Dennehy EB, Willis B, Cummings JL. Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts. Am J Geriatr Psychiatry. 2013 Jul; 21(7):607-22. PMID: 23602309; PMCID: PMC3913908.
    80. Apostolova LG, Babakchanian S, Hwang KS, Green AE, Zlatev D, Chou YY, DeCarli C, Jack CR, Petersen RC, Aisen PS, Cummings JL, Toga AW, Thompson PM. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. Alzheimer Dis Assoc Disord. 2013 Apr-Jun; 27(2):174-81. PMID: 23694947; PMCID: PMC3662002.
    81. Lauterbach EC, Cummings JL, Kuppuswamy PS. Toward a more precise, clinically--informed pathophysiology of pathological laughing and crying. Neurosci Biobehav Rev. 2013 Sep; 37(8):1893-916. PMID: 23518269.
      View in: PubMed
    82. Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Walsh RR, Zhong K. Alzheimer's disease drug development: translational neuroscience strategies. CNS Spectr. 2013 Jun; 18(3):128-38. PMID: 23472637.
      View in: PubMed
    83. Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines. CNS Neurosci Ther. 2013 May; 19(5):294-301. PMID: 23462265.
      View in: PubMed
    84. Pillai JA, Cummings JL. Clinical trials in predementia stages of Alzheimer disease. Med Clin North Am. 2013 May; 97(3):439-57. PMID: 23642580.
      View in: PubMed
    85. Molinuevo JL, Cummings JL, Dubois B, Scheltens P. Medical Clinics of North America. Early diagnosis and intervention in predementia Alzheimer's disease. Preface. Med Clin North Am. 2013 May; 97(3):xiii-xv. PMID: 23642584.
      View in: PubMed
    86. Ferris S, Cummings J, Christensen D, Doody R, Farlow M, Sabbagh M, Liu L, Mackell J, Fain R. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimers Res Ther. 2013; 5(1):12. PMID: 23433097; PMCID: PMC4055003.
    87. Cummings JL, Dubois B, Molinuevo JL, Scheltens P. International Work Group criteria for the diagnosis of Alzheimer disease. Med Clin North Am. 2013 May; 97(3):363-8. PMID: 23642575.
      View in: PubMed
    88. Kim HJ, Kang SJ, Kim C, Kim GH, Jeon S, Lee JM, Oh SJ, Kim JS, Choe YS, Lee KH, Noh Y, Cho H, Yoon CW, Chin J, Cummings JL, Lee JH, Na DL, Seo SW. The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments. Neurobiol Aging. 2013 Jul; 34(7):1913-20. PMID: 23414669.
      View in: PubMed
    89. Leuchter A, Simon SL, Daly KA, Rosenberg-Thompson S, Abrams M, Dunkin JJ, Cook IA, Newton TF, Walter DO, Cummings JL. Quantitative EEG Correlates of Outcome in Older Psychiatric Patients: Part I: Cross-Sectional and Longitudinal Assessment of Patients With Dementia. Am J Geriatr Psychiatry. 1994 Summer; 2(3):200-209. PMID: 28530933.
      View in: PubMed
    90. Senanarong V, Harnphadungkit K, Poungvarin N, Vannasaeng S, Chongwisal S, Chakorn T, Jamjumrus P, Raksthaput A, Chaichanettee S, Aoonkaew N, Udompunthurak S, Doody RS, Cummings JL. The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results. BMC Neurol. 2013 Jan 10; 13:3. PMID: 23305293; PMCID: PMC3552988.
    91. Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer's disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013; 35(1-2):1-22. PMID: 23307039.
      View in: PubMed
    92. Appleby BS, Cummings JL. Discovering new treatments for Alzheimer's disease by repurposing approved medications. Curr Top Med Chem. 2013; 13(18):2306-27. PMID: 24059463.
      View in: PubMed
    93. Trzepacz PT, Cummings J, Konechnik T, Forrester TD, Chang C, Dennehy EB, Willis BA, Shuler C, Tabas LB, Lyketsos C. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. Int Psychogeriatr. 2013 May; 25(5):707-19. PMID: 23257314; PMCID: PMC3938603.
    94. Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis. Parkinsonism Relat Disord. 2013 Mar; 19(3):295-9. PMID: 23211417.
      View in: PubMed
    95. Cummings JL, Ihl R, Herrschaft H, Hoerr R, Tribanek M. Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia. Int Psychogeriatr. 2013 Mar; 25(3):431-8. PMID: 23194852.
      View in: PubMed
    96. Cummings J, Gould H, Zhong K. Advances in designs for Alzheimer's disease clinical trials. Am J Neurodegener Dis. 2012; 1(3):205-16. PMID: 23383393; PMCID: PMC3560467.
    97. Dubois B, Gauthier S, Cummings J. The utility of the new research diagnostic criteria for Alzheimer's disease. Int Psychogeriatr. 2013 Feb; 25(2):175-7. PMID: 23148941.
      View in: PubMed
    98. Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther. 2012; 4(5):43. PMID: 23107780; PMCID: PMC3580400.
    99. Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013 Mar; 9(2):189-98. PMID: 23062850.
      View in: PubMed
    100. Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller BL, Cummings J. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2013 Mar; 9(2):176-88. PMID: 23043900; PMCID: PMC3542408.
    101. Cummings J. Alzheimer's disease diagnostic criteria: practical applications. Alzheimers Res Ther. 2012; 4(5):35. PMID: 22947665; PMCID: PMC3580392.
    102. Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2012 Sep; 27(6):421-32. PMID: 22930699.
      View in: PubMed
    103. Doody RS, Cummings JL, Farlow MR. Reviewing the role of donepezil in the treatment of Alzheimer's disease. Curr Alzheimer Res. 2012 Sep; 9(7):773-81. PMID: 22175653.
      View in: PubMed
    104. Braskie MN, Medina LD, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Thompson PM, Cummings JL, Bookheimer SY, Ringman JM. Memory performance and fMRI signal in presymptomatic familial Alzheimer's disease. Hum Brain Mapp. 2013 Dec; 34(12):3308-19. PMID: 22806961; PMCID: PMC3812259.
    105. Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, Kressig RW, Downs P, Caputo A, Strohmaier C. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012; 33(5):341-53. PMID: 22796905.
      View in: PubMed
    106. Bernick C, Cummings J, Raman R, Sun X, Aisen P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol. 2012 Jul; 69(7):901-5. PMID: 22431834.
      View in: PubMed
    107. Allen M, Zou F, Chai HS, Younkin CS, Crook J, Pankratz VS, Carrasquillo MM, Rowley CN, Nair AA, Middha S, Maharjan S, Nguyen T, Ma L, Malphrus KG, Palusak R, Lincoln S, Bisceglio G, Georgescu C, Schultz D, Rakhshan F, Kolbert CP, Jen J, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Petersen RC, Graff-Radford NR, Dickson DW, Younkin SG, Ertekin-Taner N. Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology. 2012 Jul 17; 79(3):221-8. PMID: 22722634.
      View in: PubMed
    108. Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM. Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. Arch Neurol. 2012 Jun; 69(6):757-64. PMID: 22689192; PMCID: PMC3668092.
    109. Ringman JM, Fithian AT, Gylys K, Cummings JL, Coppola G, Elashoff D, Pratico D, Moskovitz J, Bitan G. Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations. Dement Geriatr Cogn Disord. 2012; 33(4):219-25. PMID: 22584618; PMCID: PMC3568669.
    110. Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, Chow N, Kohannim O, Cummings JL, Thompson PM, Elashoff D. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging. 2013 Jan; 34(1):62-72. PMID: 22503160; PMCID: PMC3412892.
    111. Sabbagh JJ, Kinney JW, Cummings JL. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. Neurobiol Aging. 2013 Jan; 34(1):169-83. PMID: 22464953.
      View in: PubMed
    112. Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. PMID: 22393531; PMCID: PMC3282492.
    113. Ringman JM, Coppola G, Elashoff D, Rodriguez-Agudelo Y, Medina LD, Gylys K, Cummings JL, Cole GM. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement Geriatr Cogn Disord. 2012; 33(1):1-5. PMID: 22343824; PMCID: PMC3696356.
    114. Cummings JL. Food for thought: Souvenaid in mild Alzheimer’s disease. J Alzheimers Dis. 2012; 31(1):237-8. PMID: 22766771.
      View in: PubMed
    115. Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, Cole G, Sokolow S, Gylys K, Geschwind DH, Cummings JL, Wan HI. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol. 2012 Jan; 69(1):96-104. PMID: 22232349; PMCID: PMC3632731.
    116. Cummings JL. Alzheimer's disease clinical trials: changing the paradigm. Curr Psychiatry Rep. 2011 Dec; 13(6):437-42. PMID: 22052382.
      View in: PubMed
    117. Jones R, Wilkinson D, Lopez OL, Cummings J, Waldemar G, Zhang R, Mackell J, Gauthier S. Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease. Trials. 2011 Oct 26; 12:233. PMID: 22029822; PMCID: PMC3223137.
    118. Walker Z, Cummings JL. [123I]N-?-fluoropropyl-2ß-carbomethoxy-3ß-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies. Alzheimers Dement. 2012 Jan; 8(1):74-83. PMID: 22024052.
      View in: PubMed
    119. Apostolova LG, Hwang KS, Medina LD, Green AE, Braskie MN, Dutton RA, Lai J, Geschwind DH, Cummings JL, Thompson PM, Ringman JM. Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease. Dement Geriatr Cogn Disord. 2011; 32(2):118-25. PMID: 21952501; PMCID: PMC3222115.
    120. Medina LD, Rodriguez-Agudelo Y, Geschwind DH, Gilbert PE, Liang LJ, Cummings JL, Ringman JM. Propositional density and apolipoprotein E genotype among persons at risk for familial Alzheimer's disease. Dement Geriatr Cogn Disord. 2011; 32(3):188-92. PMID: 22134129; PMCID: PMC3542946.
    121. Cummings J, Reynders R, Zhong K. Globalization of Alzheimer's disease clinical trials. Alzheimers Res Ther. 2011 Aug 17; 3(4):24. PMID: 21861855; PMCID: PMC3226279.
    122. Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain. 2011 Nov; 134(Pt 11):3146-66. PMID: 21810889.
      View in: PubMed
    123. Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen PS. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. PMID: 21810649.
      View in: PubMed
    124. Cummings J. Alzheimer's disease: clinical trials and the amyloid hypothesis. Ann Acad Med Singapore. 2011 Jul; 40(7):304-6. PMID: 21870020.
      View in: PubMed
    125. Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement. 2011 May; 7(3):e13-44. PMID: 21550318.
      View in: PubMed
    126. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011 May; 43(5):436-41. PMID: 21460841.
      View in: PubMed
    127. Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol. 2011 Feb 07; 11:21. PMID: 21299848; PMCID: PMC3042005.
    128. Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O, Zhang R, Xu Y, Sun Y, Knox S, Richardson S, Mackell J. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry. 2011 Feb; 26(2):150-7. PMID: 20597141.
      View in: PubMed
    129. Braskie MN, Medina LD, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Cummings JL, Bookheimer SY, Ringman JM. Increased fMRI signal with age in familial Alzheimer's disease mutation carriers. Neurobiol Aging. 2012 Feb; 33(2):424.e11-21. PMID: 21129823; PMCID: PMC3097258.
    130. Cummings J. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? Biol Psychiatry. 2010 Nov 15; 68(10):876-8. PMID: 21035622.
      View in: PubMed
    131. Lopez OL, Schwam E, Cummings J, Gauthier S, Jones R, Wilkinson D, Waldemar G, Zhang R, Schindler R. Predicting cognitive decline in Alzheimer's disease: an integrated analysis. Alzheimers Dement. 2010 Nov; 6(6):431-9. PMID: 21044773.
      View in: PubMed
    132. Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, Hepner A, Kaye R. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010 Nov; 68(5):693-702. PMID: 20839238.
      View in: PubMed
    133. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010 Nov; 9(11):1118-27. PMID: 20934914.
      View in: PubMed
    134. Teng E, Becker BW, Woo E, Knopman DS, Cummings JL, Lu PH. Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Oct-Dec; 24(4):348-53. PMID: 20592580.
      View in: PubMed
    135. Andrawis JP, Hwang KS, Green AE, Kotlerman J, Elashoff D, Morra JH, Cummings JL, Toga AW, Thompson PM, Apostolova LG. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging. 2012 May; 33(5):856-66. PMID: 20833446; PMCID: PMC3010297.
    136. Teng E, Becker BW, Woo E, Cummings JL, Lu PH. Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord. 2010; 30(3):189-97. PMID: 20798539; PMCID: PMC2948658.
    137. Ringman JM, Medina LD, Braskie M, Rodriguez-Agudelo Y, Geschwind DH, Macias-Islas MA, Cummings JL, Bookheimer S. Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task. Cereb Cortex. 2011 Apr; 21(4):877-83. PMID: 20729396; PMCID: PMC3059887.
    138. Cummings J, Ward TH, Dive C. Fit-for-purpose biomarker method validation in anticancer drug development. Drug Discov Today. 2010 Oct; 15(19-20):816-25. PMID: 20708097.
      View in: PubMed
    139. Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR, Petersen RC, Aisen PS, Jagust WJ, Koeppe RA, Mathis CA, Weiner MW, Thompson PM. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010 Aug; 31(8):1284-303. PMID: 20538372; PMCID: PMC3051831.
    140. Gauthier S, Lopez OL, Waldemar G, Jones RW, Cummings J, Zhang R, Schindler R, Schwam E. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. Int Psychogeriatr. 2010 Sep; 22(6):973-83. PMID: 20534179.
      View in: PubMed
    141. Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. Dement Geriatr Cogn Disord. 2010; 29(5):406-12. PMID: 20502014.
      View in: PubMed
    142. Cummings JL. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol Aging. 2010 Aug; 31(8):1481-92. PMID: 20447734; PMCID: PMC2902618.
    143. Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother. 2010 May; 10(5):711-28. PMID: 20420492; PMCID: PMC4140224.
    144. Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp. 2010 May; 31(5):786-97. PMID: 20143386; PMCID: PMC2938765.
    145. Apostolova LG, Beyer M, Green AE, Hwang KS, Morra JH, Chou YY, Avedissian C, Aarsland D, Janvin CC, Larsen JP, Cummings JL, Thompson PM. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov Disord. 2010 Apr 30; 25(6):687-95. PMID: 20437538; PMCID: PMC3068920.
    146. Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010 Jun; 25(4):347-52. PMID: 20392862.
      View in: PubMed
    147. Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, Arnold SE, Mann DM, Pickering-Brown SM, Seelaar H, Heutink P, van Swieten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Hodges J, Spillantini MG, Gilman S, Lieberman AP, Kaye JA, Woltjer RL, Bigio EH, Mesulam M, Al-Sarraj S, Troakes C, Rosenberg RN, White CL, Ferrer I, Lladó A, Neumann M, Kretzschmar HA, Hulette CM, Welsh-Bohmer KA, Miller BL, Alzualde A, Lopez de Munain A, McKee AC, Gearing M, Levey AI, Lah JJ, Hardy J, Rohrer JD, Lashley T, Mackenzie IR, Feldman HH, Hamilton RL, Dekosky ST, van der Zee J, Kumar-Singh S, Van Broeckhoven C, Mayeux R, Vonsattel JP, Troncoso JC, Kril JJ, Kwok JB, Halliday GM, Bird TD, Ince PG, Shaw PJ, Cairns NJ, Morris JC, McLean CA, DeCarli C, Ellis WG, Freeman SH, Frosch MP, Growdon JH, Perl DP, Sano M, Bennett DA, Schneider JA, Beach TG, Reiman EM, Woodruff BK, Cummings J, Vinters HV, Miller CA, Chui HC, Alafuzoff I, Hartikainen P, Seilhean D, Galasko D, Masliah E, Cotman CW, Tuñón MT, Martínez MC, Munoz DG, Carroll SL, Marson D, Riederer PF, Bogdanovic N, Schellenberg GD, Hakonarson H, Trojanowski JQ, Lee VM. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010 Mar; 42(3):234-9. PMID: 20154673.
      View in: PubMed
    148. Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, Lyketsos C. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr. 2010 May; 22(3):346-72. PMID: 20096151.
      View in: PubMed
    149. Apostolova LG, Morra JH, Green AE, Hwang KS, Avedissian C, Woo E, Cummings JL, Toga AW, Jack CR, Weiner MW, Thompson PM. Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects. Neuroimage. 2010 May 15; 51(1):488-99. PMID: 20083211; PMCID: PMC2847034.
    150. Cummings JL, Ringman J, Metz K. Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative. J Alzheimers Dis. 2010; 19(2):375-88. PMID: 20110588; PMCID: PMC2855886.
    151. Cummings J, Emre M, Aarsland D, Tekin S, Dronamraju N, Lane R. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. J Alzheimers Dis. 2010; 20(1):301-11. PMID: 20164585.
      View in: PubMed
    152. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010; 20(2):509-16. PMID: 20164561.
      View in: PubMed
    153. Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clin Drug Investig. 2010; 30(1):41-9. PMID: 19995097.
      View in: PubMed
    154. Cummings JL. Commentary on: L-methylfolate, methylcobolamine, and N-acetylcysteine in the treatment of Alzheimer's disease-related cognitive decline. CNS Spectr. 2010 Jan; 15(1 Suppl 1):7. PMID: 20397370.
      View in: PubMed
    155. Cummings J, Jones R, Wilkinson D, Lopez O, Gauthier S, Waldemar G, Zhang R, Xu Y, Sun Y, Richardson S, Mackell J. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. J Alzheimers Dis. 2010; 21(3):843-51. PMID: 20634594.
      View in: PubMed
    156. Fuh JL, Cummings JL. Top cited papers in International Psychogeriatrics: 6b. Behavioral disorders and caregivers' reaction in Taiwanese patients with Alzheimer's disease. Int Psychogeriatr. 2009 Dec; 21(6):1031-6. PMID: 19781110.
      View in: PubMed
    157. Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones RW, Gauthier S, Lopez OL, Cummings J, Xu Y, Feldman HH. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 28(3):244-51. PMID: 19786776; PMCID: PMC3202931.
    158. Cummings JL. Defining and labeling disease-modifying treatments for Alzheimer's disease. Alzheimers Dement. 2009 Sep; 5(5):406-18. PMID: 19751920.
      View in: PubMed
    159. Teng E, Tingus KD, Lu PH, Cummings JL. Persistence of neuropsychological testing deficits in mild cognitive impairment. Dement Geriatr Cogn Disord. 2009; 28(2):168-78. PMID: 19707017; PMCID: PMC2814143.
    160. Ringman JM, Medina LD, Rodriguez-Agudelo Y, Chavez M, Lu P, Cummings JL. Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. Curr Alzheimer Res. 2009 Aug; 6(4):341-6. PMID: 19689233; PMCID: PMC2887763.
    161. Apostolova LG, Thompson PM, Rogers SA, Dinov ID, Zoumalan C, Steiner CA, Siu E, Green AE, Small GW, Toga AW, Cummings JL, Phelps ME, Silverman DH. Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly. Mol Imaging Biol. 2010 Apr; 12(2):218-24. PMID: 19636640; PMCID: PMC2844536.
    162. Chow TW, Binns MA, Cummings JL, Lam I, Black SE, Miller BL, Freedman M, Stuss DT, van Reekum R. Apathy symptom profile and behavioral associations in frontotemporal dementia vs dementia of Alzheimer type. Arch Neurol. 2009 Jul; 66(7):888-93. PMID: 19597092; PMCID: PMC2875777.
    163. Woods DL, Bushnell B, Kim H, Geschwind D, Cummings J. Apolipoprotein epsilon4 status is associated with behavioral symptoms in nursing home residents with dementia. Int Psychogeriatr. 2009 Aug; 21(4):722-8. PMID: 19470200.
      View in: PubMed
    164. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, Lyketsos CG. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009 May; 5(5):245-55. PMID: 19488082.
      View in: PubMed
    165. Harvey PD, Ferris SH, Cummings JL, Wesnes KA, Hsu C, Lane RM, Tekin S. Evaluation of dementia rating scales in Parkinson's disease dementia. Am J Alzheimers Dis Other Demen. 2010 Mar; 25(2):142-8. PMID: 19359706.
      View in: PubMed
    166. Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D, Peskind E, Dietrich W, Beekly DL, Kukull WA, Morris JC. The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord. 2009 Apr-Jun; 23(2):91-101. PMID: 19474567; PMCID: PMC2743984.
    167. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92. PMID: 19328434; PMCID: PMC3959165.
    168. Cummings JL. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Establishing a national biomarker database: utility and incentives. Alzheimers Dement. 2009 Mar; 5(2):108-13. PMID: 19328437.
      View in: PubMed
    169. Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J, Dickinson G, Aarons L, Lacasse E, Robson L, Dive C, Ranson M. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol. 2009 Apr 01; 27(10):1660-6. PMID: 19237630.
      View in: PubMed
    170. Alva G, Cummings JL. Relative tolerability of Alzheimer's disease treatments. Psychiatry (Edgmont). 2008 Nov; 5(11):27-36. PMID: 19724715; PMCID: PMC2695725.
    171. Cummings J. Primary progressive aphasia and the growing role of biomarkers in neurological diagnosis. Ann Neurol. 2008 Oct; 64(4):361-4. PMID: 18991355.
      View in: PubMed
    172. Cummings JL. Alzheimer's disease summit. Translating research advances into clinical practice. Introduction. CNS Spectr. 2008 Oct; 13(10 Suppl 16):4-5. PMID: 18955951.
      View in: PubMed
    173. Cummings JL. Integrating symptomatic- and disease-modifying treatments. CNS Spectr. 2008 Oct; 13(10 Suppl 16):28-30. PMID: 18955958.
      View in: PubMed
    174. Schaffer BA, Bertram L, Miller BL, Mullin K, Weintraub S, Johnson N, Bigio EH, Mesulam M, Wiedau-Pazos M, Jackson GR, Cummings JL, Cantor RM, Levey AI, Tanzi RE, Geschwind DH. Association of GSK3B with Alzheimer disease and frontotemporal dementia. Arch Neurol. 2008 Oct; 65(10):1368-74. PMID: 18852354; PMCID: PMC2841136.
    175. Cummings JL. Controversies in Alzheimer's disease drug development. Int Rev Psychiatry. 2008 Aug; 20(4):389-95. PMID: 18925488; PMCID: PMC2858263.
    176. Cascade E, Kalali AH, Cummings JL. Use of atypical antipsychotics in the elderly. Psychiatry (Edgmont). 2008 Jul; 5(7):28-31. PMID: 19727265; PMCID: PMC2695730.
    177. Teng E, Ringman JM, Ross LK, Mulnard RA, Dick MB, Bartzokis G, Davies HD, Galasko D, Hewett L, Mungas D, Reed BR, Schneider LS, Segal-Gidan F, Yaffe K, Cummings JL. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry. 2008 Jun; 16(6):469-77. PMID: 18515691; PMCID: PMC2989660.
    178. Salzman C, Jeste DV, Meyer RE, Cohen-Mansfield J, Cummings J, Grossberg GT, Jarvik L, Kraemer HC, Lebowitz BD, Maslow K, Pollock BG, Raskind M, Schultz SK, Wang P, Zito JM, Zubenko GS. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry. 2008 Jun; 69(6):889-98. PMID: 18494535; PMCID: PMC2674239.
    179. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May; 4(3):156-63. PMID: 18631960; PMCID: PMC2544623.
    180. Ringman JM, Romano JD, Medina LD, Rodriguez-Agudelo Y, Schaffer B, Varpetian A, Ortiz F, Fitten LJ, Cummings JL, Baloh RW. Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriers. Dement Geriatr Cogn Disord. 2008; 25(4):380-4. PMID: 18376127.
      View in: PubMed
    181. Farlow MR, Cummings J. A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease. Dement Geriatr Cogn Disord. 2008; 25(4):301-8. PMID: 18311077.
      View in: PubMed
    182. Cummings J, Hodgkinson C, Odedra R, Sini P, Heaton SP, Mundt KE, Ward TH, Wilkinson RW, Growcott J, Hughes A, Dive C. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol Cancer Ther. 2008 Mar; 7(3):455-63. PMID: 18347133.
      View in: PubMed
    183. Bonelli RM, Cummings JL. Frontal-subcortical dementias. Neurologist. 2008 Mar; 14(2):100-7. PMID: 18332839.
      View in: PubMed
    184. Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement. 2008 Mar; 4(2):65-79. PMID: 18631951.
      View in: PubMed
    185. Cummings JL, Miller BL, Christensen DD, Cherry D. Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease. CNS Spectr. 2008 Feb; 13(2 Suppl 2):1-20; quiz 22. PMID: 18264030.
      View in: PubMed
    186. Cummings JL, Mackell J, Kaufer D. Behavioral effects of current Alzheimer's disease treatments: a descriptive review. Alzheimers Dement. 2008 Jan; 4(1):49-60. PMID: 18631950.
      View in: PubMed
    187. Cummings JL. Optimizing phase II of drug development for disease-modifying compounds. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S15-20. PMID: 18631992.
      View in: PubMed
    188. Marshall GA, Cummings JL. Neuropsychiatric evaluation in dementia. Handb Clin Neurol. 2008; 89:53-61. PMID: 18631730.
      View in: PubMed
    189. Fillit HM, Simon ES, Doniger GM, Cummings JL. Practicality of a computerized system for cognitive assessment in the elderly. Alzheimers Dement. 2008 Jan; 4(1):14-21. PMID: 18631946.
      View in: PubMed
    190. Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord. 2008; 25(2):115-26. PMID: 18087152.
      View in: PubMed
    191. Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother. 2007 Nov; 7(11):1457-63. PMID: 17997695.
      View in: PubMed
    192. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology. 2007 Oct 16; 69(16):1622-34. PMID: 17938373.
      View in: PubMed
    193. Apostolova LG, Steiner CA, Akopyan GG, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch Neurol. 2007 Oct; 64(10):1489-95. PMID: 17923632; PMCID: PMC3197839.
    194. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 Sep 15; 22(12):1689-707; quiz 1837. PMID: 17542011.
      View in: PubMed
    195. Teng E, Lu PH, Cummings JL. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dement Geriatr Cogn Disord. 2007; 24(4):253-9. PMID: 17700021.
      View in: PubMed
    196. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007 Aug; 6(8):734-46. PMID: 17616482.
      View in: PubMed
    197. Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology. 2007 Jul 24; 69(4 Suppl 1):S10-3. PMID: 17646618.
      View in: PubMed
    198. Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol. 2007 Jul; 64(7):1015-20. PMID: 17620493.
      View in: PubMed
    199. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J Alzheimers Dis. 2007 Jul; 11(4):509-19. PMID: 17656830.
      View in: PubMed
    200. Apostolova LG, Akopyan GG, Partiali N, Steiner CA, Dutton RA, Hayashi KM, Dinov ID, Toga AW, Cummings JL, Thompson PM. Structural correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord. 2007; 24(2):91-7. PMID: 17570907.
      View in: PubMed
    201. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007 Jun; 6(6):501-12. PMID: 17509485.
      View in: PubMed
    202. Ringman JM, O'Neill J, Geschwind D, Medina L, Apostolova LG, Rodriguez Y, Schaffer B, Varpetian A, Tseng B, Ortiz F, Fitten J, Cummings JL, Bartzokis G. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain. 2007 Jul; 130(Pt 7):1767-76. PMID: 17522104.
      View in: PubMed
    203. Apostolova LG, Lu P, Rogers S, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. 3D mapping of language networks in clinical and pre-clinical Alzheimer's disease. Brain Lang. 2008 Jan; 104(1):33-41. PMID: 17485107; PMCID: PMC2211373.
    204. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med. 2007 May; 120(5):388-97. PMID: 17466645.
      View in: PubMed
    205. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007 May; 22(5):456-67. PMID: 17380489.
      View in: PubMed
    206. Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007 Apr 24; 68(17):1356-63. PMID: 17452579.
      View in: PubMed
    207. Tsang SW, Vinters HV, Cummings JL, Wong PT, Chen CP, Lai MK. Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer's disease. Neurobiol Aging. 2008 Oct; 29(10):1524-32. PMID: 17433503; PMCID: PMC2667969.
    208. Cummings JL. Involuntary emotional expression disorder: definition, diagnosis, and measurement scales. CNS Spectr. 2007 Apr; 12(4 Suppl 5):11-6. PMID: 17426670.
      View in: PubMed
    209. Teng E, Lu PH, Cummings JL. Deficits in facial emotion processing in mild cognitive impairment. Dement Geriatr Cogn Disord. 2007; 23(4):271-9. PMID: 17351319.
      View in: PubMed
    210. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer's disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol. 2007 Mar; 20(1):29-33. PMID: 17341768.
      View in: PubMed
    211. Rosen HJ, Cummings J. A real reason for patients with pseudobulbar affect to smile. Ann Neurol. 2007 Feb; 61(2):92-6. PMID: 17212357.
      View in: PubMed
    212. Cummings JL. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. Rev Neurol Dis. 2007; 4(2):57-62. PMID: 17609636.
      View in: PubMed
    213. Cummings JL. Measuring disease modification in Alzheimer's disease. CNS Spectr. 2007 Jan; 12(1 Suppl 1):11-4. PMID: 17712916.
      View in: PubMed
    214. Bonelli RM, Cummings JL. Frontal-subcortical circuitry and behavior. Dialogues Clin Neurosci. 2007; 9(2):141-51. PMID: 17726913; PMCID: PMC3181854.
    215. Cummings JL, Jeste DV. Pharmacotherapy of neuropsychiatric syndromes in neurologic disorders: definitional and regulatory aspects. Psychopharmacol Bull. 2007; 40(4):89-98. PMID: 18227780.
      View in: PubMed
    216. Maurer K, McKeith I, Cummings J, Ames D, Burns A. Has the management of Alzheimer's disease changed over the past 100 years? Lancet. 2006 Nov 04; 368(9547):1619-21. PMID: 17084762.
      View in: PubMed
    217. Apostolova LG, Dinov ID, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain. 2006 Nov; 129(Pt 11):2867-73. PMID: 17018552.
      View in: PubMed
    218. Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers Dement. 2006 Oct; 2(4):263-71. PMID: 19595897.
      View in: PubMed
    219. Tractenberg RE, Aisen PS, Weiner MF, Cummings JL, Hancock GR. Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach. Alzheimers Dement. 2006 Oct; 2(4):303-13. PMID: 19595904; PMCID: PMC3118012.
    220. Fuh JL, Lam L, Hirono N, Senanarong V, Cummings JL. Neuropsychiatric inventory workshop: behavioral and psychologic symptoms of dementia in Asia. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4):314-7. PMID: 17132981.
      View in: PubMed
    221. Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S109-23. PMID: 17135805.
      View in: PubMed
    222. Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4):210-6. PMID: 17132964.
      View in: PubMed
    223. Morris JC, Cummings JL. Workshop reports from the third Asia-pacific regional meeting of the international working group on harmonization of dementia drug guidelines. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4):313. PMID: 17132980.
      View in: PubMed
    224. Apostolova LG, Lu PH, Rogers S, Dutton RA, Hayashi KM, Toga AW, Cummings JL, Thompson PM. 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4):224-31. PMID: 17132966.
      View in: PubMed
    225. Sano M, Egelko S, Jin S, Cummings J, Clark CM, Pawluczyk S, Thomas RJ, Schittini M, Thal LJ. Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4):232-41. PMID: 17132967; PMCID: PMC3526370.
    226. Salmon DP, Cummings JL, Jin S, Sano M, Sperling RA, Zamrini E, Petersen RC, Edland SD, Thal LJ, Ferris SH. ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S139-46. PMID: 17135807.
      View in: PubMed
    227. Cummings JL, Raman R, Ernstrom K, Salmon D, Ferris SH. ADCS Prevention Instrument Project: behavioral measures in primary prevention trials. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S147-51. PMID: 17135808.
      View in: PubMed
    228. Murrell J, Ghetti B, Cochran E, Macias-Islas MA, Medina L, Varpetian A, Cummings JL, Mendez MF, Kawas C, Chui H, Ringman JM. The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics. 2006 Nov; 7(4):277-9. PMID: 16897084; PMCID: PMC3378247.
    229. Ortiz F, Fitten LJ, Cummings JL, Hwang S, Fonseca M. Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2006 Aug-Sep; 21(4):263-73. PMID: 16948291.
      View in: PubMed
    230. Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006 Jul 11; 67(1):57-63. PMID: 16832078.
      View in: PubMed
    231. Tsang SW, Pomakian J, Marshall GA, Vinters HV, Cummings JL, Chen CP, Wong PT, Lai MK. Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease. Neurobiol Aging. 2007 Sep; 28(9):1381-7. PMID: 16828202.
      View in: PubMed
    232. Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry. 2006 Jul; 14(7):605-12. PMID: 16816014.
      View in: PubMed
    233. Cummings JL, Arciniegas DB, Brooks BR, Herndon RM, Lauterbach EC, Pioro EP, Robinson RG, Scharre DW, Schiffer RB, Weintraub D. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr. 2006 06; 11(S6):1-7. PMID: 16816786.
      View in: PubMed
    234. Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol. 2006 May; 63(5):693-9. PMID: 16682538.
      View in: PubMed
    235. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B. Mild cognitive impairment. Lancet. 2006 Apr 15; 367(9518):1262-70. PMID: 16631882.
      View in: PubMed
    236. Allen RT, Tasto JP, Cummings J, Robertson CM, Amiel D. Meniscal debridement with an arthroscopic radiofrequency wand versus an arthroscopic shaver: comparative effects on menisci and underlying articular cartilage. Arthroscopy. 2006 Apr; 22(4):385-93. PMID: 16581450.
      View in: PubMed
    237. Cummings J. Alzheimer's disease clinical trials: where are we now? Can J Neurol Sci. 2006 Feb; 33(1):5. PMID: 16583716.
      View in: PubMed
    238. Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord. 2006 Feb; 21(2):148-58. PMID: 16211591.
      View in: PubMed
    239. Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GW, Phelps ME. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A. 2006 Jan 17; 103(3):702-7. PMID: 16407119; PMCID: PMC1334681.
    240. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord. 2006; 21(3):144-7. PMID: 16391476.
      View in: PubMed
    241. Bartzokis G, Lu PH, Geschwind DH, Edwards N, Mintz J, Cummings JL. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. Arch Gen Psychiatry. 2006 Jan; 63(1):63-72. PMID: 16389198.
      View in: PubMed
    242. Cummings JL. What we can learn from open-label extensions of randomized clinical trials. Arch Neurol. 2006 Jan; 63(1):18-9. PMID: 16401732.
      View in: PubMed
    243. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of activities of daily living in Alzheimer disease. Alzheimer Dis Assoc Disord. 2006 Jan-Mar; 20(1):56-9. PMID: 16493237.
      View in: PubMed
    244. Cummings JL, Zhong K. Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nat Rev Drug Discov. 2006 Jan; 5(1):64-74. PMID: 16485346.
      View in: PubMed
    245. Ringman JM, Cummings JL. Current and emerging pharmacological treatment options for dementia. Behav Neurol. 2006; 17(1):5-16. PMID: 16720956.
      View in: PubMed
    246. Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, Reback E, Porter V, Swerdloff R, Cummings JL. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006 Feb; 63(2):177-85. PMID: 16344336.
      View in: PubMed
    247. Van Lancker Sidtis D, Pachana N, Cummings JL, Sidtis JJ. Dysprosodic speech following basal ganglia insult: toward a conceptual framework for the study of the cerebral representation of prosody. Brain Lang. 2006 May; 97(2):135-53. PMID: 16271755.
      View in: PubMed
    248. Cummings JL. Behavioral and neuropsychiatric outcomes in Alzheimer's disease. CNS Spectr. 2005 Nov; 10(11 Suppl 18):22-5. PMID: 16273027.
      View in: PubMed
    249. McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005 Nov; 4(11):735-42. PMID: 16239180.
      View in: PubMed
    250. Cummings JL, Koumaras B, Chen M, Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother. 2005 Sep; 3(3):137-48. PMID: 16257816.
      View in: PubMed
    251. Cummings JL. The neuropsychiatric burden of neurological diseases in the elderly. Int Psychogeriatr. 2005 Sep; 17(3):341-51. PMID: 16252369.
      View in: PubMed
    252. Tasto JP, Cummings J, Medlock V, Hardesty R, Amiel D. Microtenotomy using a radiofrequency probe to treat lateral epicondylitis. Arthroscopy. 2005 Jul; 21(7):851-60. PMID: 16012499.
      View in: PubMed
    253. Morris JC, Cummings J. Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. J Alzheimers Dis. 2005 Jun; 7(3):235-9; discussion 255-62. PMID: 16006667.
      View in: PubMed
    254. Shin IS, Carter M, Masterman D, Fairbanks L, Cummings JL. Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry. 2005 Jun; 13(6):469-74. PMID: 15956266.
      View in: PubMed
    255. Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O'Connor SM, Carter MF, Amezcua H, Cummings JL. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol. 2005 May; 62(5):721-8. PMID: 15883258.
      View in: PubMed
    256. Cummings JL. Searching for methods to detect, prevent, and treat Alzheimer's disease. Am J Psychiatry. 2005 Apr; 162(4):645-7. PMID: 15800132.
      View in: PubMed
    257. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr; 53(4):695-9. PMID: 15817019.
      View in: PubMed
    258. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res. 2005 Apr; 2(2):131-6. PMID: 15974909; PMCID: PMC1702408.
    259. Senanarong V, Poungvarin N, Jamjumras P, Sriboonroung A, Danchaivijit C, Udomphanthuruk S, Cummings JL. Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's disease. Int Psychogeriatr. 2005 Mar; 17(1):81-90. PMID: 15945593.
      View in: PubMed
    260. Cummings JL. Clinical evaluation as a biomarker for Alzheimer's disease. J Alzheimers Dis. 2005 Mar; 8(4):327-37. PMID: 16556964.
      View in: PubMed
    261. Tractenberg RE, Weiner MF, Cummings JL, Patterson MB, Thal LJ. Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach. J Neuropsychiatry Clin Neurosci. 2005; 17(1):51-60. PMID: 15746483; PMCID: PMC4377284.
    262. Cummings JL, Altman J. Genotype, proteotype, phenotype relationships in neurodegenerative diseases. Highlights from the 21st Ipsen Foundation Alzheimer's Disease Symposium, September 13, 2004, Paris, France. Rev Neurol Dis. 2005; 2(2):80-4. PMID: 19813301.
      View in: PubMed
    263. Cummings JL, Tractenberg RE, Gamst A, Teri L, Masterman D, Thal LJ. Regression to the mean: implications for clinical trials of psychotropic agents in dementia. Curr Alzheimer Res. 2004 Nov; 1(4):323-8. PMID: 15975061; PMCID: PMC4371726.
    264. Cummings JL. Dementia with lewy bodies: molecular pathogenesis and implications for classification. J Geriatr Psychiatry Neurol. 2004 Sep; 17(3):112-9. PMID: 15312274.
      View in: PubMed
    265. Senanarong V, Jamjumras P, Harmphadungkit K, Klubwongs M, Udomphanthurak S, Poungvarin N, Vannasaeng S, Cummings JL. A counseling intervention for caregivers: effect on neuropsychiatric symptoms. Int J Geriatr Psychiatry. 2004 Aug; 19(8):781-8. PMID: 15290702.
      View in: PubMed
    266. Assal F, Alarcón M, Solomon EC, Masterman D, Geschwind DH, Cummings JL. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 2004 Aug; 61(8):1249-53. PMID: 15313842.
      View in: PubMed
    267. Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cummings JL. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging. 2004 Aug; 25(7):843-51. PMID: 15212838.
      View in: PubMed
    268. Cummings JL. Alzheimer's disease. N Engl J Med. 2004 Jul 01; 351(1):56-67. PMID: 15229308.
      View in: PubMed
    269. Cummings JL. Fluctuations in cognitive function in dementia with Lewy bodies. Lancet Neurol. 2004 May; 3(5):266. PMID: 15099536.
      View in: PubMed
    270. Swanberg MM, Tractenberg RE, Mohs R, Thal LJ, Cummings JL. Executive dysfunction in Alzheimer disease. Arch Neurol. 2004 Apr; 61(4):556-60. PMID: 15096405; PMCID: PMC4419376.
    271. Waltz JA, Knowlton BJ, Holyoak KJ, Boone KB, Back-Madruga C, McPherson S, Masterman D, Chow T, Cummings JL, Miller BL. Relational integration and executive function in Alzheimer's disease. Neuropsychology. 2004 Apr; 18(2):296-305. PMID: 15099152.
      View in: PubMed
    272. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004 Mar; 161(3):532-8. PMID: 14992980.
      View in: PubMed
    273. Kang SJ, Choi SH, Lee BH, Jeong Y, Hahm DS, Han IW, Cummings JL, Na DL. Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI). J Geriatr Psychiatry Neurol. 2004 Mar; 17(1):32-5. PMID: 15018695.
      View in: PubMed
    274. Bartzokis G, Tishler TA, Shin IS, Lu PH, Cummings JL. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci. 2004 Mar; 1012:224-36. PMID: 15105269.
      View in: PubMed
    275. Cummings JL, Silverman D, Small G, Phelps M. The role of positron emission tomography in the diagnosis of Alzheimer's disease. J Am Geriatr Soc. 2004 Mar; 52(3):467-8; author reply 468-9. PMID: 14962169.
      View in: PubMed
    276. Cummings JL. The one-minute mental status examination. Neurology. 2004 Feb 24; 62(4):534-5. PMID: 14981165.
      View in: PubMed
    277. Fu C, Chute DJ, Farag ES, Garakian J, Cummings JL, Vinters HV. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med. 2004 Jan; 128(1):32-8. PMID: 14692815.
      View in: PubMed
    278. Cummings J, Zelcer N, Allen JD, Yao D, Boyd G, Maliepaard M, Friedberg TH, Smyth JF, Jodrell DI. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol. 2004 Jan 01; 67(1):31-9. PMID: 14667926.
      View in: PubMed
    279. Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord. 2004 Jan-Mar; 18(1):17-21. PMID: 15195459.
      View in: PubMed
    280. Cummings JL. Reconsidering diagnostic criteria for dementia with lewy bodies. Highlights from the Third International Workshop on Dementia with Lewy Bodies and Parkinson's Disease Dementia, September 17-20, 2003, Newcastle Upon Tyne, United Kingdom. Rev Neurol Dis. 2004; 1(1):31-4. PMID: 16397449.
      View in: PubMed
    281. Chong MS, Vinters HV, Gustavson AR, Cummings JL. Dementia with parkinsonism: what is the diagnosis? Rev Neurol Dis. 2004; 1(1):41-4. PMID: 16397452.
      View in: PubMed
    282. Cummings JL. Treatment of Alzheimer's disease: current and future therapeutic approaches. Rev Neurol Dis. 2004; 1(2):60-9. PMID: 16400259.
      View in: PubMed
    283. Chong MS, Klement IA, Vinters HV, Cummings JL. Dementia with parkinsonism. Rev Neurol Dis. 2004; 1(2):97-101. PMID: 16400266.
      View in: PubMed
    284. Tractenberg RE, Singer CM, Cummings JL, Thal LJ. The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. J Sleep Res. 2003 Dec; 12(4):331-7. PMID: 14633245; PMCID: PMC4418643.
    285. Gustavson AR, Cummings JL. Cholinesterase inhibitors in non-Alzheimer dementias. J Am Med Dir Assoc. 2003 Nov-Dec; 4(6 Suppl):S165-9. PMID: 14613594.
      View in: PubMed
    286. Silverman DH, Truong CT, Kim SK, Chang CY, Chen W, Kowell AP, Cummings JL, Czernin J, Small GW, Phelps ME. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab. 2003 Nov; 80(3):350-5. PMID: 14680983.
      View in: PubMed
    287. Mendez MF, Clark DG, Shapira JS, Cummings JL. Speech and language in progressive nonfluent aphasia compared with early Alzheimer's disease. Neurology. 2003 Oct 28; 61(8):1108-13. PMID: 14581673.
      View in: PubMed
    288. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord. 2004; 17(1-2):100-8. PMID: 14564129.
      View in: PubMed
    289. Cummings JL. Toward a molecular neuropsychiatry of neurodegenerative diseases. Ann Neurol. 2003 Aug; 54(2):147-54. PMID: 12891666.
      View in: PubMed
    290. Solomon DH, Wenger NS, Saliba D, Young RT, Adelman AM, Besdine RK, Blazer DG, Cassell CK, Cummings JL, Katz PR, Kitzman DW, Lavizzo-Mourey RJ, Mondoux LC, Popovich R, Pories WJ, Wenger N. Appropriateness of quality indicators for older patients with advanced dementia and poor prognosis. J Am Geriatr Soc. 2003 Jul; 51(7):902-7. PMID: 12834508.
      View in: PubMed
    291. Senanarong V, Harnphadungkit K, Prayoonwiwat N, Poungvarin N, Sivasariyanonds N, Printarakul T, Udompunthurak S, Cummings JL. A new measurement of activities of daily living for Thai elderly with dementia. Int Psychogeriatr. 2003 Jun; 15(2):135-48. PMID: 14620072.
      View in: PubMed
    292. Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Smith GE, Geda YE, Cummings JL, Petersen RC, Sunderland T. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry. 2003 May; 160(5):857-66. PMID: 12727688.
      View in: PubMed
    293. Sobrido MJ, Miller BL, Havlioglu N, Zhukareva V, Jiang Z, Nasreddine ZS, Lee VM, Chow TW, Wilhelmsen KC, Cummings JL, Wu JY, Geschwind DH. Novel tau polymorphisms, tau haplotypes, and splicing in familial and sporadic frontotemporal dementia. Arch Neurol. 2003 May; 60(5):698-702. PMID: 12756133; PMCID: PMC2072863.
    294. Cummings JL. The impact of depressive symptoms on patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2003 Apr-Jun; 17(2):61-2. PMID: 12794380.
      View in: PubMed
    295. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):131-45. PMID: 12611743.
      View in: PubMed
    296. Bartzokis G, Cummings JL, Sultzer D, Henderson VW, Nuechterlein KH, Mintz J. White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol. 2003 Mar; 60(3):393-8. PMID: 12633151.
      View in: PubMed
    297. Boyle PA, Malloy PF, Salloway S, Cahn-Weiner DA, Cohen R, Cummings JL. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):214-21. PMID: 12611751.
      View in: PubMed
    298. Sultzer DL, Brown CV, Mandelkern MA, Mahler ME, Mendez MF, Chen ST, Cummings JL. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. Am J Psychiatry. 2003 Feb; 160(2):341-9. PMID: 12562582.
      View in: PubMed
    299. Cummings JL. Alzheimer's disease: from molecular biology to neuropsychiatry. Semin Clin Neuropsychiatry. 2003 Jan; 8(1):31-6. PMID: 12567330.
      View in: PubMed
    300. Porter VR, Buxton WG, Fairbanks LA, Strickland T, O'Connor SM, Rosenberg-Thompson S, Cummings JL. Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. J Neuropsychiatry Clin Neurosci. 2003; 15(2):180-6. PMID: 12724459.
      View in: PubMed
    301. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Jeste DV, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF, Rovner BW, Steffens DC, Unützer J, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer's disease: description and review. Expert Rev Neurother. 2003 01; 3(1):99-106. PMID: 19810852.
      View in: PubMed
    302. Cummings JL. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography in Alzheimer's diagnosis: time for technology transfer. Mol Imaging Biol. 2002 Nov; 4(6):385-6. PMID: 14537102.
      View in: PubMed
    303. Back-Madruga C, Boone KB, Briere J, Cummings J, McPherson S, Fairbanks L, Thompson E. Functional ability in executive variant Alzheimer's disease and typical Alzheimer's disease. Clin Neuropsychol. 2002 Aug; 16(3):331-40. PMID: 12607146.
      View in: PubMed
    304. Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol. 2002 Aug; 15(4):445-50. PMID: 12151841.
      View in: PubMed
    305. Tekin S, Cummings JL. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res. 2002 Aug; 53(2):647-54. PMID: 12169339.
      View in: PubMed
    306. Chow TW, Miller BL, Boone K, Mishkin F, Cummings JL. Frontotemporal dementia classification and neuropsychiatry. Neurologist. 2002 Jul; 8(4):263-9. PMID: 12803685.
      View in: PubMed
    307. Silverman DH, Cummings JL, Small GW, Gambhir SS, Chen W, Czernin J, Phelps ME. Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol. 2002 Jul; 4(4):283-93. PMID: 14537119.
      View in: PubMed
    308. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, Mittman B. Guidelines for managing Alzheimer's disease: Part II. Treatment. Am Fam Physician. 2002 Jun 15; 65(12):2525-34. PMID: 12086242.
      View in: PubMed
    309. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, Mittman B. Guidelines for managing Alzheimer's disease: part I. Assessment. Am Fam Physician. 2002 Jun 01; 65(11):2263-72. PMID: 12074525.
      View in: PubMed
    310. Ringman JM, Diaz-Olavarrieta C, Rodriguez Y, Fairbanks L, Cummings JL. The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in Mexico. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Jun; 15(2):99-105. PMID: 12050472.
      View in: PubMed
    311. Cummings JL, Cole G. Alzheimer disease. JAMA. 2002 May 08; 287(18):2335-8. PMID: 11988038.
      View in: PubMed
    312. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF, Rovner BW, Steffens DC, Tariot PN, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry. 2002 Mar-Apr; 10(2):125-8. PMID: 11925273.
      View in: PubMed
    313. McPherson S, Fairbanks L, Tiken S, Cummings JL, Back-Madruga C. Apathy and executive function in Alzheimer's disease. J Int Neuropsychol Soc. 2002 Mar; 8(3):373-81. PMID: 11939696.
      View in: PubMed
    314. Doraiswamy PM, Leon J, Cummings JL, Marin D, Neumann PJ. Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2002 Mar; 57(3):M173-7. PMID: 11867654.
      View in: PubMed
    315. Wood S, Cummings JL, Schnelle B, Stephens M. A videotape-based training method for improving the detection of depression in residents of long-term care facilities. Gerontologist. 2002 Feb; 42(1):114-21. PMID: 11815706.
      View in: PubMed
    316. Swanberg MM, Cummings JL. Benefit-risk considerations in the treatment of dementia with Lewy bodies. Drug Saf. 2002; 25(7):511-23. PMID: 12093309.
      View in: PubMed
    317. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002; 13(2):67-73. PMID: 11844887.
      View in: PubMed
    318. Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rummans TA, Kaufer DI, LaFrance WC, Coffey CE. Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 2002; 14(4):377-405. PMID: 12426407.
      View in: PubMed
    319. Sultzer DL, Chen ST, Brown CV, Mahler ME, Cummings JL, Hinkin CH, Mandelkern MA. Subcortical hyperintensities in Alzheimer's disease: associated clinical and metabolic findings. J Neuropsychiatry Clin Neurosci. 2002; 14(3):262-9. PMID: 12154149.
      View in: PubMed
    320. Cummings JL. The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. Int J Neuropsychopharmacol. 2000 Jul; 3(7):21-29. PMID: 11343621.
      View in: PubMed
    321. Cummings JL, Fairbanks L, Masterman DL. Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease. Int J Neuropsychopharmacol. 1999 Mar; 2(1):59-66. PMID: 11281971.
      View in: PubMed
    322. Chow TW, Cummings JL. Treatment of Depression in the Patient with Parkinson's Disease. Clin Geriatr. 1998 Oct; 6(11):34-46. PMID: 28529443.
      View in: PubMed
    Jeffrey's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _